The sustained selling by the largest activist holder at progressively lower prices signals waning conviction and potential further distribution. Monitor for additional 13D amendments or a move below the 5% threshold, which would remove the activist overhang but also signal a complete exit.
Price Chart
Executive Summary
5AM Partners VII, LLC and affiliated entities filed Amendment No. 6 to their Schedule 13D on Skye Bioscience, reporting a 25.7% beneficial ownership stake (1,194,443 shares) as of September 22, 2026, post-1-for-8 reverse split. The filing reveals significant open-market and block sales by 5AM entities in August and September 2026, reducing their position from the prior filing. The stated purpose remains unchanged, but the active selling signals de-escalation and reduced conviction.
Key Financial Metrics
Key Facts
- 5AM entities collectively own 1,194,443 shares (25.7% of 4,427,677 shares outstanding as of August 11, 2026, post-reverse split).
- Andrew J. Schwab beneficially owns 1,218,088 shares (26.1%) including 23,645 shares from exercisable stock options.
- 5AM Ventures VII holds 981,269 common shares and 213,174 shares issuable upon warrant exercise.
- Since the prior amendment (August 18, 2026), 5AM entities sold a total of 191,447 shares in open-market and block transactions between August 19 and September 23, 2026.
- Sales were executed at declining prices: $2.80 (Aug 19-20), $1.91 (Sep 16), $1.65 (Sep 22 block), and $1.61 (Sep 23).
- The filing references the August 14, 2026 Transaction Agreement with Redx Pharma Limited and a related Securities Purchase Agreement.
- The 1-for-8 reverse stock split was effected on August 24, 2026.
Financial Impact
5AM entities sold approximately 191,447 shares for an estimated total of ~$320,000-$350,000 based on disclosed prices, representing a ~14% reduction in their disclosed position.
Risk Factors
- Continued insider selling could pressure the stock further.
- The activist's reduced stake may weaken their influence over the Redx Pharma acquisition process.
- The stock's decline from $2.80 to $1.61 during the selling period suggests weak market demand.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0001873545-26-000009 |
| Document: 0001873545-26-000009-index.html | 0001873545-26-000009 |
| Document: 0001873545-26-000009.txt | 0001873545-26-000009 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | PREM14A | — | awaiting T+20 | — | — |
Oct 14, 2026 12d ago | SC 13G | $1.59 | awaiting T+20 | — | $1.57 (−1.26%) |
Sep 24, 2026 4w ago | Insider Cluster | $1.67 $1.54 | ▼ −7.78% | ▼ −6.31% | $1.57 (−5.99%) |
Sep 24, 2026 4w ago | SC 13D/A | $1.67 $1.54 | ▲ +7.78% | ▲ +6.31% | $1.57 (+5.99%) |
Sep 18, 2026 5w ago | Insider Cluster | $1.78 $1.53 | ▲ +14.04% | ▲ +13.14% | $1.57 (+11.80%) |
Aug 19, 2026 9w ago | DEFA14A | $0.2809 $0.2206 | ▼ −21.46% | ▼ −21.34% | $1.57 (+458.92%) |
Aug 14, 2026 10w ago | 8-K | $0.5015 $0.2487 | ▼ −50.40% | ▼ −48.41% | $1.57 (+213.06%) |
Aug 14, 2026 10w ago | Press Release | $0.5015 $0.2487 | ▲ +50.40% | ▲ +48.41% | $1.57 (−213.06%) |
May 15, 2026 23w ago | 8-K | $0.7780 $0.7184 | ▲ +7.66% | ▲ +9.24% | $1.57 (−101.80%) |
May 12, 2026 23w ago | Press Release | $0.8140 $0.7800 | ▲ +4.18% | ▲ +2.45% | $1.57 (−92.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers